Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Patients With Rectal Cancer
NCT07711509Active, not recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2025
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous fecal microbiota transplantation in low anterior resection syndrome (LARS), fecal incontinence (FI), diversion colitis (DC) and 1 more, sponsored by Peking University People's Hospital. Primary endpoint: Low Anterior Resection Syndrome Score. Started Mar 2025; status: active, not recruiting.
02
Drugs
autologous fecal microbiota transplantation
03
Conditions
low anterior resection syndrome (LARS)fecal incontinence (FI)diversion colitis (DC)Gut microbiota dysbiosis
Beyond the preview
Go deeper on NCT07711509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711509.